Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Phase I/II study of tandutinib (MLN518) plus standard induction chemotherapy in newly diagnosed acute myelogeneous leukemia (AML)

Phase I/II study of tandutinib (MLN518) plus standard induction chemotherapy in newly diagnosed acute myelogeneous leukemia (AML). Blood. 2006; 108:51a.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.